Skip to content

US · CRNX · BIOTECHNOLOGY

Crinetics Pharmaceuticals, Inc. (CRNX) intrinsic value and stock valuation

$84.95as of 2026-11-21 · Mkt cap 8.91B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Crinetics Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values CRNX with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from CRNX’s statements →

Crinetics Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 crinetics.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$7.7M+156% 5y CAGRd
20162025
Net income
-$-465.32M
20162025
Free cash flow
-$-383.68M
20162025
Total equity
$992.1M+42.5% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$7.7M$1.04M$4.01M$4.74M$1.08M
Operating income-$-516.77M-$-338.85M-$-222.61M-$-167.88M-$-107.7M
Net income-$-465.32M-$-298.41M-$-214.53M-$-163.92M-$-107.64M
EPSd-$-4.95M-$-3.69M-$-3.69M-$-3.15M-$-2.8M
Operating cash flow-$-377.92M-$-225.97M-$-166.31M-$-115.2M-$-88.59M
Capital expenditure-$-5.76M-$-3.84M-$-4.69M-$-1.66M-$-440K
Free cash flow-$-383.68M-$-229.81M-$-171M-$-116.86M-$-89.02M
Total assets$1.14B$1.43B$635.4M$352.2M$351M
Total debt$48.5M$51.7M$51.7M$3.08M$4.01M
Net debt-$-52.99M-$-212.82M-$-3.17M-$-29.6M-$-196.68M
Total equity$992.1M$1.32B$539.1M$316.3M$331.9M
Cash and short-term investments$1.03B$1.35B$558.6M$334.4M$333.7M
Income statement
20252024202320222021
Revenue$7.7M$1.04M$4.01M$4.74M$1.08M
Cost of revenue$1.08M$0.00$0.00$0.00$0.00
Gross profit$6.62M$1.04M$4.01M$4.74M$1.08M
Research and development expenses$332.1M$240.2M$168.5M$130.2M$84.3M
Selling, general and administrative expenses$191.3M$99.7M$58.1M$42.4M$24.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$523.4M$339.9M$226.6M$172.6M$108.8M
Cost and expenses$524.5M$339.9M$226.6M$172.6M$108.8M
Interest income$52M$41.4M$13.4M$4.32M$160K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$3.89M$2.79M$1.1M$980K$920K
Ebitda-$-461.25M-$-295.62M-$-213.43M-$-162.94M-$-106.72M
Operating income-$-516.77M-$-338.85M-$-222.61M-$-167.88M-$-107.7M
Total other income/expenses, net$51.6M$40.5M$8.08M$3.96M$60K
Income before tax-$-465.14M-$-298.41M-$-214.53M-$-163.92M-$-107.64M
Income tax expense$180K$0.00$0.00$0.00$0.00
Net income-$-465.32M-$-298.41M-$-214.53M-$-163.92M-$-107.64M
Weighted average shares outstanding$94.1M$80.8M$58.1M$52M$38.4M
Weighted average diluted shares outstanding$94.1M$80.8M$58.1M$52M$38.4M
Balance sheet
20252024202320222021
Cash and short-term investments$1.03B$1.35B$558.6M$334.4M$333.7M
Net receivables$590K$8.47M$9.35M$2.42M$2.03M
Inventory$2.02M$0.00$0.00$0.00$0.00
Total current assets$1.05B$1.38B$574.2M$345.2M$344.7M
Property, plant and equipment, net$54.8M$55.6M$57.4M$4.99M$4.72M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$800K$800K$1.77M$1.97M$1.01M
Total non-current assets$87.2M$59.2M$61.2M$6.99M$6.29M
Total assets$1.14B$1.43B$635.4M$352.2M$351M
Accounts payable$22.6M$5.85M$6.55M$6.88M$4.27M
Short-term debt$6.49M$7.15M$4.17M$1.05M$940K
Deferred revenue$1.24M$2.18M$2.06M$2.24M$0.00
Total current liabilities$85.1M$59.7M$43.9M$27.7M$16M
Long-term debt$42.1M$44.6M$47.6M$2.02M$3.07M
Deferred revenue, non-current$3.81M$4.7M$4.75M$6.1M$0.00
Total non-current liabilities$58.3M$50.1M$52.3M$8.12M$3.08M
Capital lease obligations$42.1M$51.7M$47.6M$2.02M$3.07M
Total liabilities$143.4M$109.8M$96.3M$35.9M$19.1M
Common stock$2.41B$2.28B$1.19B$759.4M$607.6M
Retained earnings-$-1.42B-$-952.11M-$-653.7M-$-439.17M-$-275.25M
Accumulated other comprehensive income (loss)$1.75M$960K$980K-$-3.93M-$-380K
Total equity$992.1M$1.32B$539.1M$316.3M$331.9M
Total investments$926.4M$1.09B$505.4M$303.7M$134M
Total debt$48.5M$51.7M$51.7M$3.08M$4.01M
Net debt-$-52.99M-$-212.82M-$-3.17M-$-29.6M-$-196.68M
Cash flow statement
20252024202320222021
Net income-$-465.32M-$-298.41M-$-214.53M-$-163.92M-$-107.64M
Depreciation and amortization$3.89M$2.79M$1.1M$980K$920K
Stock-based compensation$91M$69.4M$40.9M$28.3M$17.4M
Change in working capital$4.84M$11.6M$8.04M$18.6M$1.1M
Accounts receivable-$-590K$17.5M$14.7M$11M$6.29M
Inventory-$-2.02M$0.00$0.00$0.00-$-6.29M
Accounts payable$29M$0.00$0.00$0.00$6.29M
Net cash provided by operating activities-$-377.92M-$-225.97M-$-166.31M-$-115.2M-$-88.59M
Investments in property, plant and equipment-$-5.76M-$-3.84M-$-4.69M-$-1.66M-$-440K
Acquisitions, net$0.00$0.00$0.00$0.00$420K
Net cash used for investing activities$173.9M-$-574.82M-$-200.41M-$-173.98M-$-56.48M
Common stock issued$40.6M$970.1M$369M$117.2M$249.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$40.6M$1.01B$388.9M$122M$252.7M
Net change in cash-$-163.51M$209.7M$22.2M-$-167.22M$107.6M
Cash at end of period$102.3M$265.9M$56.2M$34M$201.2M
Operating cash flow-$-377.92M-$-225.97M-$-166.31M-$-115.2M-$-88.59M
Capital expenditure-$-5.76M-$-3.84M-$-4.69M-$-1.66M-$-440K
Free cash flow-$-383.68M-$-229.81M-$-171M-$-116.86M-$-89.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Crinetics Pharmaceuticals, Inc.

        Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

        CEO
        R. Scott Struthers
        Employees
        594
        Beta
        0.13

        Explore

        Frequently asked questions

        What is the intrinsic value of Crinetics Pharmaceuticals, Inc. (CRNX)?

        Crinetics Pharmaceuticals, Inc. (CRNX) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CRNX undervalued?

        CRNX trades at a price of $84.95 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.